Antibody Information
General Information of This Antibody
Antibody ID | ANI0VMMXB |
|||||
---|---|---|---|---|---|---|
Antibody Name | Rolinsatamab |
|||||
Organization | AbbVie Inc. |
|||||
Indication | Breast cancer |
|||||
Synonyms |
h16f; PR-1594804
Click to Show/Hide
|
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Chimeric IgG1-kappa |
|||||
Antigen Name | Prolactin receptor (PRLR) |
Antigen Info | ||||
Click to Show/Hide the Sequence Information of This Antibody | ||||||
Heavy Chain Sequence |
EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNY
NQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PCVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
Heavy Chain Varible Domain |
EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNY
NQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 2 |
APELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
Heavy Chain CDR 1 |
GYTFTTYW
Click to Show/Hide
|
|||||
Heavy Chain CDR 2 |
IDPSDSYS
Click to Show/Hide
|
|||||
Heavy Chain CDR 3 |
ARNGGLGPAWFSY
Click to Show/Hide
|
|||||
Light Chain Sequence |
DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPS
RFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Light Chain Varible Domain |
DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPS
RFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK Click to Show/Hide
|
|||||
Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Light Chain CDR 1 |
QYVGTA
Click to Show/Hide
|
|||||
Light Chain CDR 2 |
SAS
Click to Show/Hide
|
|||||
Light Chain CDR 3 |
QQYSSYPWT
Click to Show/Hide
|
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Rolinsatamab talirine [Phase 1]
Identified from the Human Clinical Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Objective Response Rate (ORR) |
0.00%
|
|||
Patients Enrolled |
Locally advanced or metastatic solid tumor types associated with PRLR expression, including breast cancer, colorectal cancer, and adrenocortical carcinoma. Patients had progressed on prior treatment, were not amenable to treatment with curative intent, and had no other therapy options known to provide clinical benefit, or were ineligible for such therapies. Patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate bone marrow, renal, and hepatic function.
Click to Show/Hide
|
||||
Administration Dosage |
Initial dose was 2.70 ug/kg, dose increment was capped at a 100% increase, or at a 50% increase if a grade2 drug-related toxicity had been observed, intravenously every 21 days.
|
||||
Related Clinical Trial | |||||
NCT Number | NCT03145909 | Clinical Status | Phase 1 | ||
Clinical Description |
A phase 1 study evaluating the safety, pharmacokinetics and anti-tumor activity of ABBV-176 in subjects with advanced solid tumors likely to express prolactin receptor (PRLR).
|
||||
Primary Endpoint |
MtD was not formally determined, as identification of a tolerable dose was confounded by late-onset toxicities. ABBV-176 was associated with significant toxicity in this phase 1, dose-escalation study.
|
||||
Other Endpoint |
No patient had an objective response.
|
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.50% | |||
Method Description |
Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.5 mg/kg.
|
||||
In Vivo Model | BT-474 CDX | ||||
In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | |||
Method Description |
Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.1 mg/kg.
|
||||
In Vivo Model | BT-474 CDX | ||||
In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | |||
Method Description |
Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.3 mg/kg.
|
||||
In Vivo Model | BT-474 CDX | ||||
In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.50 pM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Invasive breast carcinoma | T-47D cells | CVCL_0553 | ||
Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.01 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Breast adenocarcinoma | CAMA-1 cells | CVCL_1115 | ||
Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.01 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Prostate carcinoma | 22RV1 cells | CVCL_1045 | ||
Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.11 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Colon adenocarcinoma | SW403 cells | CVCL_0545 | ||
Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.16 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Ovarian clear cell adenocarcinoma | SMOV-2 cells | CVCL_S920 | ||
Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.24 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.26 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.32 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.60 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Endometrial adenocarcinoma | AN3-CA cells | CVCL_0028 | ||
Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.77 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.20 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Adult hepatocellular carcinoma | Huh-7 cells | CVCL_0336 | ||
Experiment 12 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.60 nM
|
|||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Hepatoblastoma | Hep-G2 cells | CVCL_0027 | ||
Experiment 13 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 22.00 nM | |||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Invasive breast carcinoma of no special type | UACC-812 cells | CVCL_1781 | ||
Experiment 14 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 22.00 nM | |||
Method Description |
The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
|
||||
In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.